JP2015505843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505843A5 JP2015505843A5 JP2014546255A JP2014546255A JP2015505843A5 JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5 JP 2014546255 A JP2014546255 A JP 2014546255A JP 2014546255 A JP2014546255 A JP 2014546255A JP 2015505843 A5 JP2015505843 A5 JP 2015505843A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- biologically active
- pharmaceutical composition
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576034P | 2011-12-15 | 2011-12-15 | |
| US61/576,034 | 2011-12-15 | ||
| PCT/CA2012/050899 WO2013086636A1 (en) | 2011-12-15 | 2012-12-14 | Soluble igf receptor fc fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505843A JP2015505843A (ja) | 2015-02-26 |
| JP2015505843A5 true JP2015505843A5 (enExample) | 2016-02-04 |
Family
ID=48611766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546255A Pending JP2015505843A (ja) | 2011-12-15 | 2012-12-14 | 可溶性ＩＧＦレセプターＦｃ融合タンパク質およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10538575B2 (enExample) |
| EP (1) | EP2791338B1 (enExample) |
| JP (1) | JP2015505843A (enExample) |
| KR (1) | KR20150031217A (enExample) |
| CN (1) | CN104066845A (enExample) |
| BR (1) | BR112014014418A2 (enExample) |
| CA (1) | CA2858389A1 (enExample) |
| HK (1) | HK1202587A1 (enExample) |
| WO (1) | WO2013086636A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2016094456A1 (en) * | 2014-12-08 | 2016-06-16 | 1Globe Health Institute Llc | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
| EA033821B1 (ru) * | 2015-06-04 | 2019-11-29 | Ospedale San Raffaele Srl | Применение ингибитора оси igfbp3/tmem219 для лечения диабета |
| CN107921094B (zh) * | 2015-06-04 | 2022-03-01 | 圣拉斐尔医院有限公司 | Igfbp3及其用途 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| CN106520806B (zh) * | 2016-11-03 | 2018-06-19 | 宜明细胞生物科技有限公司 | 一种重组car基因及其载体、car-t细胞和应用 |
| EP3632929A1 (en) | 2018-10-02 | 2020-04-08 | Ospedale San Raffaele S.r.l. | Antibodies and uses thereof |
| CN113092392B (zh) * | 2021-03-05 | 2022-11-08 | 苏州西山中科药物研究开发有限公司 | 一种检测猴血清中靶向可溶性蛋白的单克隆抗体药物总浓度的通用型方法 |
| CN119708266B (zh) * | 2025-02-26 | 2025-06-06 | 首玺(广州)医疗科技有限责任公司 | 一种胰岛素样生长因子-1连接多肽及其在子宫内膜损伤修复中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861267A4 (en) | 1995-11-14 | 2000-02-02 | Univ Jefferson | INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1 |
| DK1699822T3 (da) * | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| MY146381A (en) * | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| US7713521B2 (en) * | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
| TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
| GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| KR20090114449A (ko) * | 2007-02-14 | 2009-11-03 | 글락소 그룹 리미티드 | Ｉｇｆ-ⅰｒ에 대한 항체 |
| WO2008108986A2 (en) | 2007-03-02 | 2008-09-12 | Amgen Inc. | Methods and compositions for treating tumor diseases |
| US20110262430A1 (en) | 2007-08-01 | 2011-10-27 | Jonathan Henry Ellis | Novel antibodies |
| WO2010003108A2 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| WO2010003118A1 (en) * | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
| JP2011529452A (ja) * | 2008-07-29 | 2011-12-08 | ザ・ロイヤル・インスティテューション・フォア・ザ・アドバンスメント・オブ・ラーニング／マクギル・ユニヴァーシティ | 抗血管新生薬としての可溶性ｉｇｆ受容体 |
| AU2009299793B2 (en) | 2008-10-01 | 2016-03-10 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| WO2010136480A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
-
2012
- 2012-12-14 JP JP2014546255A patent/JP2015505843A/ja active Pending
- 2012-12-14 CA CA2858389A patent/CA2858389A1/en not_active Abandoned
- 2012-12-14 WO PCT/CA2012/050899 patent/WO2013086636A1/en not_active Ceased
- 2012-12-14 CN CN201280067765.6A patent/CN104066845A/zh active Pending
- 2012-12-14 BR BR112014014418A patent/BR112014014418A2/pt not_active IP Right Cessation
- 2012-12-14 HK HK15103272.6A patent/HK1202587A1/xx unknown
- 2012-12-14 EP EP12857915.8A patent/EP2791338B1/en active Active
- 2012-12-14 KR KR20147019486A patent/KR20150031217A/ko not_active Withdrawn
- 2012-12-14 US US14/365,250 patent/US10538575B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505843A5 (enExample) | ||
| Corre et al. | The osteosarcoma microenvironment: a complex but targetable ecosystem | |
| Qazi et al. | Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma | |
| JP6857498B2 (ja) | 癌を処置するための併用方法 | |
| Yu et al. | Potential approaches to the treatment of Ewing's sarcoma | |
| Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
| JP2015529641A5 (enExample) | ||
| JP2018521135A5 (enExample) | ||
| CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
| JP2017171685A5 (enExample) | ||
| EA200701250A1 (ru) | Иммуноконъюгаты против интегрина, способы и варианты применения | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2016535009A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| JP2017534259A5 (enExample) | ||
| US20220056450A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| JP2019506862A5 (enExample) | ||
| JP2013511559A5 (enExample) | ||
| JP2014523398A5 (enExample) | ||
| Zhao et al. | IL10-modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition | |
| JP2023532032A (ja) | 血液脳関門浸透アプタマー及びその利用 | |
| JP2018509423A5 (enExample) | ||
| Luo et al. | Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma | |
| JP2014525412A5 (enExample) | ||
| CN106924260B (zh) | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |